Back to News
Market Impact: 0.3
Merck's KEYTRUDA QLEX Approved In Japan For Subcutaneous Use
Source: Nasdaq
Healthcare & BiotechProduct LaunchesRegulation & Legislation
Japan's Ministry of Health, Labor and Welfare approved Merck's KEYTRUDA QLEX, a subcutaneous formulation combining pembrolizumab with berahyaluronidase alfa-pmph. The approval expands Merck's oncology treatment-administration options in Japan and could support KEYTRUDA franchise convenience and adoption.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.45
Ticker Sentiment
MRK0.65
More News
- Moderna raises 2026 outlook as CEO says newer vaccines are gaining traction
- Halozyme falls 6% as raised guidance fails to impress investors
- HALOZYME REPORTS THIRD QUARTER 2026 RESULTS AND RAISES FULL YEAR 2026 FINANCIAL GUIDANCE
- Tech stock rout, driven by US AI fears, continues in Asian trading
- ‘The nail that sticks out gets hammered first’: Elon Musk’s net worth falls $113 billion from Tesla and SpaceX drops
- Stock Selloff Eases After $3 Trillion Rout